Nervgen Pharma (NGEN) Divestments (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Divestments came in at $6133.3 in Q1 2026, down 65.12% year-over-year from $17584.6 in Q1 2025, and down 66.32% quarter-over-quarter from $18209.5 in Q2 2025.
Powered by 
Analysis
Nervgen Pharma (NGEN) Divestments (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Divestments for 2 consecutive years, with $6133.3 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Divestments fell 65.12% year-over-year to $6133.3 in Q1 2026; TTM through Jun 2026 was $41927.5, a N/A change from a year earlier, with the FY2025 full-year figure at $72372.7, up 68.3% from the prior year.
- Divestments was $6133.3 for Q1 2026 at Nervgen Pharma, down from $18209.5 in the prior quarter.
- Over five years, Divestments peaked at $18209.5 in Q2 2025 and troughed at $6133.3 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Nervgen Pharma | 156.23 Mn | 156.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 6,133.35 |
| Jun 30, 2025 | 18,209.53 |
| Mar 31, 2025 | 17,584.60 |